China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals is a China-based pharmaceutical company that researches, develops, manufactures, markets and sells traditional Chinese medicine products (TCMP) through Taizhou Suxuantang, an entity it manages under contractual arrangements. Its products include Advanced TCMP, which can be taken orally or after soaking in hot water without decoction, and Regular TCMP for hospitals and drug stores. Its portfolio also includes raw medicinal materials. China SXT makes money by selling its products to hospitals, especially traditional Chinese medicine hospitals, pharmaceutical wholesalers and distributors, and chain pharmacies. Wholesalers distribute products to hospitals and other healthcare distributors. As of March 31, 2026, its end-customer base includes 46 pharmaceutical companies, 11 chain pharmacies and 12 hospitals in 5 provinces and municipalities in China. Its principal executive offices are in Taizhou, Jiangsu, China.
No enriched coverage for $SXTC in the last 7 days.
No SEC Form 4 filings for $SXTC in the last 30 days.
See all $SXTC insider activity →China SXT Pharmaceuticals (SXTC) announced a 1-for-100 share consolidation, effective October 26, 2026. Outstanding shares will reduce from 68.7 million to 686,775. The stock is currently trading at $0.05, down 31.51%.
China SXT Pharmaceuticals (SXTC) rose 7% after terminating an additional purchase right tied to its recent offering. Imunon (IMNN) surged 18% following a deal to sell ThermoDox rights, potentially receiving $16.5M in milestone payments. HeartSciences (HSCS) gained 13% after filing a proxy statement for a proposed merger with Fortitude Mining, creating a digital asset mining platform.
China SXT Pharmaceuticals Inc. (SXTC) ended a $12M additional purchase right for its Oct. 8, 2026 offering. Existing securities remain unaffected. The company did not announce new financing plans or updates on capital needs.
Recent SXTC coverage spans corporate actions, market movers and earnings.
The consolidation reduces share count dramatically, likely causing further price pressure as the market adjusts to the new share structure.
Removal of the purchase right reduces dilution risk.
The cancellation reduces potential dilution and signals limited immediate financing need.
Dilutive financing risk from the registered direct offering likely drives downside for SXTC.
Shares declined following capital raise announcement.
AlphAI scores every news story that mentions SXTC with an AI model for sentiment and relevance, and aggregates insider trades from China SXT Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
China SXT Pharmaceuticals (SXTC) announced a 1-for-100 share consolidation, effective October 26, 2026. Outstanding shares will reduce from 68.7 million to 686,775. The stock is currently trading at $0.05, down 31.51%.
1 min readChina SXT Pharmaceuticals (SXTC) rose 7% after terminating an additional purchase right tied to its recent offering. Imunon (IMNN) surged 18% following a deal to sell ThermoDox rights, potentially receiving $16.5M in milestone payments. HeartSciences (HSCS) gained 13% after filing a proxy statement for a proposed merger with Fortitude Mining, creating a digital asset mining platform.
2 min readChina SXT Pharmaceuticals Inc. (SXTC) ended a $12M additional purchase right for its Oct. 8, 2026 offering. Existing securities remain unaffected. The company did not announce new financing plans or updates on capital needs.
1 min readThe Dow Jones gained 200 points, while NASDAQ and S&P 500 showed mixed results. Chipotle shares fell 4% after Starbucks denied acquisition rumors. First Tracks Biotherapeutics, J-Star Holding, and Euro Tech Holdings rose, while Service Properties Trust, China SXT Pharmaceuticals, and TTM Technologies declined. Commodities saw oil rise and gold fall. European and Asian markets also showed mixed results.
7 min readU.S. stocks were mixed on Monday, with the Dow up 0.4% and Nasdaq down 0.2%. Enovix (ENVX) shares surged after reporting a 38% year-over-year revenue increase to $11M. Other movers: MNDR +289%, YMAT +72%, CLWT +68%, DKI -51%, SXTC -35%, VIVK -34%. Oil rose 1.4%, gold fell 0.5%. European and Asian markets showed mixed results.
2 min readU.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.
3 min readChina SXT Pharmaceuticals (SXTC) announced a $12M registered direct offering, selling 8M shares at $1.50 each, plus warrants. The offering is expected to close on Oct 9, 2026, with Univest Securities as the placement agent. The company plans to use the proceeds for general corporate purposes.
1 min readChina SXT Pharmaceuticals (SXTC) shares surged 536% post-share consolidation, with recent financing plans. VERAXA Biotech (VRXA) rose 15% after adopting FDA-aligned methodologies. ArriVent BioPharma (AVBP) gained 12% despite a missed Phase 3 trial endpoint. SciSparc (SPRC) climbed 8% on quantum analysis advancements.
3 min readChina SXT Pharmaceuticals Inc. (SXTC) shares surged 28.78% on August 18, 2026, driven by investor optimism and speculative trading. The stock's recent volatility follows a significant price jump from $0.06–$0.12 in late July to $3–$5 in mid-August, likely due to a reverse stock split. The company reported $1.14M in revenue, $34.8M in total assets, and $28.2M in cash, with a price-to-book ratio of 0.07 and negative return on capital. Traders are focusing on the stock's volatile price action rathe
4 min readChina SXT Pharmaceuticals (NASDAQ:SXTC) shares fell 77% after it announced a $9 million registered direct offering. The company will sell 4.5 million units at $2.00 each, with each unit including one Class A share and a warrant exercisable at $3.20, expiring in one year. Closing is expected around July 24, 2025.
3 min read
